The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncology

References

• Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine. Panel on cost-effectiveness in health and medicine. JAMA. 1996;276(14):1172–1177.
   PubMed Web of Science ®Google Scholar
• Siegel JE, Weinstein MC, Russell LB, et al. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276(16):1339–1341.
   PubMed Web of Science ®Google Scholar
• Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276(15):1253–1258.
   PubMed Web of Science ®Google Scholar
• Gold M, Siegel J, Russell L, Weinstein MC (Eds). Cost-effectiveness in health and medicine. Oxford University Press; Oxford, UK. 1996.
   Google Scholar
• Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ. 1997;16(1):33–64.
   PubMed Web of Science ®Google Scholar
• Johannesson M, Meltzer D, O’Conor RM. Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension. Med Decis Making. 1997;17(4):382–389.
   PubMed Web of Science ®Google Scholar
• Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ. 1997;16(1):1–31.
   PubMed Web of Science ®Google Scholar
• Cutler DM. The lifetime costs and benefits of medical technology. J Health Econ. 2007;26(6):1081–1100.
   PubMed Web of Science ®Google Scholar
• Lee RH. Future costs in cost effectiveness analysis. J Health Econ. 2008;27(4):809–818.
   PubMed Web of Science ®Google Scholar
• van Baal PH, Feenstra TL, Hoogenveen RT, et al. Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a ‘perfect’ cost-utility ratio. Health Econ. 2007;16(4):421–433.
   PubMed Web of Science ®Google Scholar
• Rappange DR, van Baal PH, van Exel NJ, et al. Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions? Pharmacoeconomics. 2008;26(10):815–830.
   PubMed Web of Science ®Google Scholar
• Methods for the development of NICE public health guidance [Internet]. 2nd ed. 2009 [cited 2014 Jul 20]. Available from: https://www.nice.org.uk/proxy/?sourceUrl=http%3A%2F%2Fwww.nice.org.uk%2Fmedia%2FCE1%2FF7%2FCPHE_Methods_manual_LR.pdf
   Google Scholar
• Neumann PJ, Thorat T, Shi J, et al. The changing face of the cost-utility literature, 1990–2012. Value Health. 2015;18(2):271–277.
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Greenberg D, Olchanski NV, et al. Growth and quality of the cost-utility literature, 1976–2001. Value Health. 2005;8(1):3–9.
   PubMed Web of Science ®Google Scholar
• Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103(2):117–128.
   PubMed Web of Science ®Google Scholar
• Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008;100(9):630–641.
   PubMed Web of Science ®Google Scholar
• Health care costs: a primer. The Kaiser Family Foundation [Internet]; 2012 [cited 2013 Jan]. Available from: https://kaiserfamilyfoundation.files.wordpress.com/2013/01/7670-03.pdf
   Google Scholar
• Karnon J, Brown J. Tamoxifen plus chemotherapy versus tamoxifen alone as adjuvant therapies for node-positive postmenopausal women with early breast cancer: a stochastic economic evaluation. Pharmacoeconomics. 2002;20(2):119–137.
   PubMed Web of Science ®Google Scholar
• Groot MT, Lugtenburg PJ, Hornberger J, et al. Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands. Eur J Haematol. 2005;74(3):194–202.
   PubMed Web of Science ®Google Scholar
• Best JH, Hornberger J, Proctor SJ, et al. Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma. Value Health. 2005;8(4):462–470.
   PubMed Web of Science ®Google Scholar
• Hornberger JC, Best JH. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer. 2005;103(8):1644–1651.
   PubMed Web of Science ®Google Scholar
• Gil JM, Rubio-Terres C, Del CA, et al. Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer. Clin Transl Oncol. 2006;8(5):339–348.
   PubMedGoogle Scholar
• Aballea S, Boler A, Craig A, et al. An economic evaluation of oxaliplatin for the adjuvant treatment of colon cancer in the United Kingdom (UK). Eur J Cancer. 2007;43(11):1687–1693.
   PubMed Web of Science ®Google Scholar
• Aballea S, Chancellor JV, Raikou M, et al. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer. 2007;109(6):1082–1089.
   PubMed Web of Science ®Google Scholar
• Liberato NL, Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2007;25(6):625–633.
   PubMed Web of Science ®Google Scholar
• Kasteng F, Erlanson M, Hagberg H, et al. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden. Acta Oncol. 2008;47(6):1029–1036.
   PubMed Web of Science ®Google Scholar
• Hornberger J, Reyes C, Lubeck D, et al. Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma. Leuk Lymphoma. 2008;49(2):227–236.
   PubMed Web of Science ®Google Scholar
• Hisashige A, Yoshida S, Kodaira S. Cost-effectiveness of adjuvant chemotherapy with uracil-tegafur for curatively resected stage III rectal cancer. Br J Cancer. 2008;99(8):1232–1238.
   PubMed Web of Science ®Google Scholar
• Retel VP, Joore MA, Knauer M, et al. Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer. Eur J Cancer. 2010;46(8):1382–1391.
   PubMed Web of Science ®Google Scholar
• Ishiguro H, Kondo M, Hoshi SL, et al. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan. Clin Ther. 2010;32(2):311–326.
   PubMed Web of Science ®Google Scholar
• Ray JA, Carr E, Lewis G, et al. An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin’s lymphoma in the UK. Value Health. 2010;13(4):346–357.
   PubMed Web of Science ®Google Scholar
• Deconinck E, Miadi-Fargier H, Pen CL, et al. Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation. Pharmacoeconomics. 2010;28(1):35–46.
   PubMed Web of Science ®Google Scholar
• Grann VR, Patel PR, Jacobson JS, et al. Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers. Breast Cancer Res Treat. 2011;125(3):837–847.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Del Muro JG, Grande E, et al. A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System. J Clin Pharm Ther. 2010;35(4):429–438.
   PubMed Web of Science ®Google Scholar
• Tolley K, Oliver N, Miranda E, et al. Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients. J Med Econ. 2010;13(3):559–570.
   PubMedGoogle Scholar
• Delea TE, Taneja C, Sofrygin O, et al. Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer. Clin Breast Cancer. 2010;10(4):267–274.
   PubMed Web of Science ®Google Scholar
• Soini EJ, Martikainen JA, Nousiainen T. Treatment of follicular non-Hodgkin’s lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up. Ann Oncol. 2011;22(5):1189–1197.
   PubMed Web of Science ®Google Scholar
• Lal LS, Byfield SD, Chang EL, et al. Cost-effectiveness analysis of a randomized study comparing radiosurgery with radiosurgery and whole brain radiation therapy in patients with 1 to 3 brain metastases. Am J Clin Oncol. 2012;35(1):45–50.
   PubMed Web of Science ®Google Scholar
• Casciano R, Chulikavit M, Di LG, et al. Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib. Value Health. 2011;14(6):846–851.
   PubMed Web of Science ®Google Scholar
• Moller J, Nicklasson L, Murthy A. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib. J Med Econ. 2011;14(6):690–697.
   PubMedGoogle Scholar
• Hoyle M, Rogers G, Moxham T, et al. Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia. Value Health. 2011;14(8):1057–1067.
   PubMed Web of Science ®Google Scholar